Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tirelizumab, Carboplatin, and Albumin-bound Paclitaxel in Resectable HNSCC
NCT05941338Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Major Pathologic Response at 6 weeks and Adverse Events. Started Mar 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05941338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941338.